CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016

Similar documents
Patient-Centered Primary Care Scorecard Measures

RULES SPECIFICATIONS VERSION: 1.8 DATE: SEPTEMBER 9, 2010 CLASS.: PROPRIETARY, FOR CLIENT USE AUTHORS: Y. CHIANG

Clinical Quality Measures Summary of Upcoming Enhancements

Quality Payment Program: Cardiology Specialty Measure Set

Meaningful Use Clinical Quality Measures for Eligible Professionals

Quality Payment Program: Cardiology Specialty Measure Set

For Electronic Measure Specification Information go to:

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Clinical Quality Measures for Submission by Medicare or Medicaid EP/s for the 2011 and 2012 Payment Year

Consensus Core Set: Cardiovascular Measures Version 1.0

Clinical Quality Measures

Patient-Centered Primary Care Scorecard Measure Specifications

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

MHSPHP Metrics Forum. Diabetes.

CLINICAL QUALITY MEASURES Stage 1 Meaningful Use

Quality Care Plus 2015 Primary Care Physician Incentive Program. Now includes Medicare patients!

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Supplement materials:

2016 Internal Medicine Preferred Specialty Measure Set

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

Practice-Level Executive Summary Report

Key Quality of Care Measures. Blue Cross Blue Shield of Michigan Traditional, PPO and POS Members. Fourth Quarter 2003

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Meaningful Use Criteria for Pediatric Providers

Meaningful Use for Eligible Providers

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

NQF Measure Number & PQRI Implementation Number

Efficiency Methodology

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

2016 General Practice/Family Practice Preferred Specialty Measure Set

The University of Mississippi School of Pharmacy

Quality Measures MIPS CV Specific

Exploring Temporal Patterns in Hypertensive Drug Therapy

Supplementary Online Content

QUALITY IMPROVEMENT Section 9

Preferred Care Partners. HEDIS Technical Standards

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Care Facilitation Quality Improvement Report

AMCP Webinar Series. Exchanges and Qualified Health Plans: How your voice can shape the future of quality reporting 14 January 2014.

Together 2 Goal Campaign Measurement Specifications American Medical Group Foundation Version 1.0 February 23, 2016

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

TENNCARE Bundled Payment Initiative: Description of Bundle Risk Adjustment for Wave 4 Episodes

2015 Healthy Heart. Program Evaluation. Our mission is to improve the health and quality of life of our members

Anthem Blue Precision Quality Designation Methodology Summary 2017

Presentation title. Better Health Care For Greater Cleveland Learning Collaborative March 5, Ron Adams, MD Regional Chief Internal Medicine

Trends in Health Plan Design: High Performance Networks. John Bertko, F.S.A., MAAA Vice President and Chief Actuary Humana Inc July 28, 2005

Cardiovascular Health and Diabetes Screening for People with Schizophrenia

Commissioning for value focus pack

Physician Profile. Revised For January 1, 2005 December 31, 2007

Title: Automatic External Defibrillators Division: Medical Management Department: Utilization Management

HEART FAILURE QUALITY IMPROVEMENT. American Heart Association Shawni Smith Regional Director, Quality & Systems Improvement

NATIONAL QUALITY FORUM

Coronary intravascular ultrasound (IVUS)

Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual

4. Which survey program does your facility use to get your program designated by the state?

Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists

The CSAC will review recommendations from the Cardiovascular 2015 project during its January 12, 2016 conference call.

THE NATIONAL QUALITY FORUM

HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications

Ischemic Heart Disease Interventional Treatment

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

MEASURING CARE QUALITY

Fractional Flow Reserve (FFR) and instant wave-free Ratio (The ifr modality)

Symmetry Episode Treatment Groups

The Future of Cardiac Care: Managing Our Patients Together

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

RCCO Quality Indicators Crosswalk

SCORES FOR 4 TH QUARTER, RD QUARTER, 2014

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

2017 Cardiology Survival Guide

Chapter 4: Cardiovascular Disease in Patients with CKD

Risk of Myocardial Infarction With Combination Antihypertensive Regimens Including a Dihydropyridine Calcium Channel Blocker in Hypertensive Diabetics

Supplementary Appendix

COMMUNITY HEALTH GROUP HEDIS MEASURES (CY 2012) MEDICARE QUICK REFERENCE GUIDE FOR BILLING DEPARTMENT

A Prospective Comparison of Two Commercially Available Hospital Admission Risk Scores

hypertension Head of prevention and control of CVD disease office Ministry of heath

Validating and Reporting the 2017 UDS Clinical Measures (Version 1)

Ischemic Heart Disease Interventional Treatment

The American Experience

Evolution of Heart Failure Disease Management at a Large VA Medical Center. Richard S. Schofield MD, FACC North Florida/South Georgia VHS

Chapter 8: Cardiovascular Disease in Patients with ESRD

Comprehensive ESRD Care (CEC) Model Proposed Quality Measures for Public Comment. Table of Contents

FastTest. You ve read the book now test yourself

UTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST

Antihypertensive Trial Design ALLHAT

Hypertension Update Clinical Controversies Regarding Age and Race

Update in Cardiology What s Hot in 2017?

Chapter 4: Cardiovascular Disease in Patients With CKD

Symmetry Episode Treatment Groups

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

(For items 1-12, each question specifies mark one or mark all that apply.)

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

CLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

Prevention of Heart Failure: What s New with Hypertension

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

SUPPLEMENTAL MATERIAL

Long-Term Care Updates

LRE Executive Dashboard Integrated Care Delivery Platform (ICDP)

Transcription:

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique occurrence of a particular illness or injury, or a year of claims for a chronic condition. The claims that are grouped include the medical, ancillary, ambulatory surgical, other hospital, emergency, inpatient, and pharmacy services that are involved in diagnosing and treating the patient s condition. The diagnosis codes on these claims also describe a patient s underlying clinical conditions related to the episode and complications and comorbidities. The services within an episode may be provided by more than one physician; the episode is attributed to a single provider based on an evaluation of the claims data to determine which provider was responsible for the overall management of the care that the patient received during the course of his or her treatment for that illness, injury, or chronic condition. WHAT IS AN EPISODE TREATMENT GROUP (ETG)? ETGs are a clinical condition classification methodology that categorizes clinically homogeneous episodes into groups. Each episode is assigned to a unique group (an episode treatment group) and its severity level is assessed (reflecting the primary clinical condition for the episode and the complications, comorbidities and patient characteristics that impact treatment). For more information see the white paper written by Optum, who developed the Symmetry ETG Grouper used by CPII, by going to www.mass.gov/gic/cpiidetails >> Information For Providers >> Scoring Methodology and access the link under Efficiency Score. EFFICIENCY REPORTS There may be up to three (3) different Efficiency Reports included in your reporting package. You will receive a Summary of Episode Treatment Groups (ETGs) report (Report A) that summarizes the top ten (10) ETGs that contribute to your overall Efficiency Score. If you were less efficient than you peers in any of your top five (5) ETGs shown on this report, you will also receive an ETG Summary report (Report B) and an ETG Detail report (Report C). The flow chart included in this package shows how these reports relate to each other. An explanation of each report including some key terms follows. A. Summary of Episode Treatment Groups (ETGs) This report summarizes the ETGs that contribute to your Efficiency Score. At the top of the report you will see your overall Efficiency Score. In the middle of the report are two (2) charts. The pie chart displays your top five (5) ETGs in terms of cost relative to all other ETGs contributing to your 1

Efficiency Score. The bar chart displays these same top five (5) ETGs in terms of your Proxy Cost as compared to peer Proxy Costs for the same ETG. At the bottom of the report, you will see your top ten (10) ETGs having the highest Proxy Cost, broken out and compared to the Proxy Costs of your peers for the same number of ETGs. Also shown is your performance relative to your peers in the form of an abacus chart. Using Total Unweighted Proxy Cost, these abacus charts show your percentile rank within your specialty, where the middle of the chart represents the median cost for the ETG. B. ETG Summary If you receive an ETG Summary report, it is because you scored as less efficient than your peers for the particular ETG. This report focuses on six (6) service categories: Medical/Professional, Ambulatory Surgery, Outpatient, Emergency, Inpatient and Pharmacy. There are two (2) charts on this report. The first chart displays your total Proxy Cost in each service category for the ETG and compares to peer Proxy Costs. The second chart shows how much more or less your Proxy Costs were than those of your peers in each of these service categories for this ETG. C. ETG Detail If you receive an ETG Detail report, it is because you were scored as less efficient than your peers for the particular ETG. This report focuses on the Medical/Professional Services category for the ETG. At the top of the report you will see your overall Efficiency Score and the count of this ETG that was attributed to you. In the middle of the report are two (2) charts. The pie chart displays the top five (5) procedures in terms of Proxy Cost relative to all other procedures contributing to the Medical/Professional Services total. The bar chart displays these same top five (5) procedures in terms of your Proxy Cost as compared to peer Proxy Cost. At the bottom, you will see your top ten (10) procedures having the highest Proxy Cost, broken out and compared to the Proxy Costs of your peers. Also shown is your performance relative to your peers in the form of an abacus chart. Using Total Unweighted Proxy Cost, these abacus charts show your percentile rank within your specialty, where the middle of the chart represents the median cost for the same service. The claims data that we analyze for this project include the most recent three years of commercial claims data from the GIC s six health plans. Occasionally, a procedure code is retired and is deleted from the current CPT-ICD9 manual, but, because we are still using this data, the procedure code appears as del_12345. Since the report includes the top procedures by frequency impacting that specific episode, a procedure with a retired code may appear on the report. Additionally, the procedure code and/or Procedure Description may be unavailable as well, resulting in a blank space. Definition of Terms Used In Efficiency Reports: Medical/Professional: The total proxy price amount for claims identified as professional, supplemental or auxiliary services based on CPT/HCPCS codes for a particular episode type. 2

Ambulatory Surgery: The total proxy price amount for claims identified for surgical or related purposes primarily based on revenue codes for a particular episode type. Outpatient: The total proxy price amount for claims identified for hospital services based on revenue codes, but not categorized as Inpatient, Ambulatory Surgery or Emergency for a particular episode type. Emergency: The total proxy price amount for claims identified for emergency room services based on revenue codes for a particular episode type Inpatient: The total proxy price amount for claims identified for inpatient services based on revenue codes for a particular episode type. Pharmacy: The total proxy price amount for claims submitted for prescription drugs for a particular episode type Efficiency Score Your Efficiency Score is created by comparing the consumption of resources (office visits, labs, medications, etc.) used in treating your patients to that of your peers treating patients with similar clinical conditions, adjusted for the severity of your patient case mix. Resource use is measured by Proxy Cost (see explanation below). The most efficient providers have lower Efficiency Scores; lessefficient providers have higher scores. Proxy Cost The unweighted costs shown for each ETG are derived using standardized costs (or proxy values) for each service included in the ETG, rather than the actual amount paid. This proxy value removes the influence of differing contract terms across health plans. The proxy values shown in these reports are not severity-adjusted (see Unweighted Total Cost below); however, each provider s ETGs are severityadjusted as part of the process of calculating the Efficiency Score. Unweighted Total Cost When determining a provider s Efficiency Score, up to three (3) years of historical data are used and the most recent year is weighted the most heavily. Additionally, a provider s raw score is adjusted for the severity of their patient case mix. Unweighted Total Cost represents the data where each year receives the same weighting and there is no severity adjustment. 3

Quality Detail Report Provider Name: Provider Specialty: NON-INTERVENTIONAL CARDIOLOGY Provider ID: IS Your Overall Score: 0.874 Measure ID Name and brief description of measure 11373 Lipid Rx noncompliance (NQF) This measure identifies patients on a lipid medication who have remained adherent to taking the medication regularly. 174 Hypertension avoid SA DHP calcium channel blocker This measure identifies the percentage of patients with hypertension diagnosed before the measurement year who had fewer than 2 prescription claims for short-acting dihydropyridine calcium channel blockers (SA DHP CCB) within the past 6 months. 185 Dyslipidemia new med 3 month lipid panel (NQF) This measure identifies patients who started lipid-lowering medication during the measurement year and had a lipid panel checked within 3 months after starting drug therapy. 395 HEDIS ACEI or ARB annual potassium and creatinine This measure identifies patients age 18 or older who received at least 180 days suppy for ACE inhibitors or ARBs during the measurement year who had at least 1 serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) test during the measurement year. 175 CHF avoid DHP calcium channel blocker This measure identifies patients with HF who are not taking a non-dihydropyridine calcium channel blocker (non-dhp CCB). 11398 HTN had creatinine test This measure identifies patients with hypertension and receiving an ACE inhibitor or ARB, who had a serum creatinine test during the measurement year. 11941 Atrial fibrillation and stroke risk on warfarin (NQF) This measure identifies patients with atrial fibrillation and other stroke risk who are taking oral anticoagulants. 172 Diabetes and hypertension or nephropathy patients on ACE-I or ARB This measure identifies patients with diabetes plus hypertension or nephropathy who are taking an ACE inhibitor or ARB during the measurement year. 398 CHD post-mi on ACE inhibitor (NQF) This measure identifies patients with ST elevation MI (STEMI), or non-st elevation MI (NSTEMI) plus a history of hypertension, HF, and/or diabetes prior to the measurement year who are taking an ACEI or an ARB during the measurement year. 3798 CHD cholesterol management This measure identifies patients 18-75 years old discharged alive for acute myocardial infarction (AMI), coronary bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) during the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during or in the year prior to the measurement year, who had a LDL-C check during the measurement year. Your number of observations for this measure Your Compliance Rate 1 Peer Compliance Rate 2 Your Percentile Rank 3 12 66.67% 88.98% 1st 11 100% 99.97% 1st 4 25% 43.34% N/A 3 66.67% 88.48% N/A 3 100% 91.33% N/A 3 66.67% 92.98% N/A 2 100% 84.58% N/A 2 100% 77.4% N/A 2 100% 68.42% N/A 2 100% 89.45% N/A 1 How often you follow the measure 2 How often your peers followed the measure 3 The percentage of your peers whose compliance rate was lower than yours